Close
Nordic 9Nordic 9

Cancer Focus Fund (investor - Venture Capital)

United States cancerfocusfund.com
See something wrong or missing? Let us know
Offices:Houston

The Cancer Focus Fund is an oncology-focused investment fund which invests in compelling cancer therapies at or near the FDA Phase 1 or Phase 2 human clinical trial regimen.

Average round investment:4.5M USD
Average number per year:1.0
Distribution: 2024 (1)
Portfolio companies: Germany Eisbach
Mostly invests in: Germany Germany (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Cancer Focus Fund

Name Criteria
Germany Peppermint Venture Partners
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Friedrich Georg Hoepfner
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Andreas Ehn
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United Kingdom Jude Gomila
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United States Cybernetix Ventures
83%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Germany MediVentures GmbH
82%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Wieland Capital
82%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany SARSTEDT AG & Co. KG
82%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Germany Aescuvest
82%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Germany J.C.M.B. Beteiligungs
82%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top